Table 13 Anticancer activity results (IC50 and IC90 µM) of compounds (25a–25e)
From: Benzimidazole scaffolds as promising antiproliferative agents: a review
Compounds | Cancer cell lines | IC50 | Doxorubicin | IC90 | Doxorubicin |
|---|---|---|---|---|---|
25a | HEPG2 | 0.55 ± 0.05 | 0.59 ± 0.03 | 7.53 ± 0.06 | 6.82 ± 0.06 |
25b | HEPG2 | 0.55 ± 0.03 | 0.59 ± 0.03 | 7.62 ± 0.09 | 6.82 ± 0.06 |
25c | MCF7 | 2.15 ± 0.04 | 0.72 ± 0.08 | 11.70 ± 0.17 | 8.77 ± 0.06 |
25d | MCF7 | 2.83 ± 0.03 | 0.72 ± 0.08 | 12.63 ± 0.09 | 8.77 ± 0.06 |
HCT 116 | 3.72 ± 0.03 | 0.65 ± 0.09 | 12.02 ± 0.07 | 7.32 ± 0.09 | |
25e | MCF7 | 2.85 ± 0.15 | 0.65 ± 0.09 | 13.25 ± 0.13 | 8.77 ± 0.06 |
HCT 116 | 3.75 ± 0.16 | 0.72 ± 0.08 | 12.05 ± 0.06 | 7.32 ± 0.09 |